Slide Four:

The primary efficacy end-point was DVT demonstrated by venography at day 6 (+ or - 2). The secondary end-point was DVT demonstrated by another venogram at the end of the 35-day study period. Bleeding complications were recorded locally at the individual study sites and then adjudicated by a central committee using a widely accepted classification for bleeding.

Previous slide

Next slide

Back to first slide

View graphic version